Compass Capital Management Inc. Has $56.87 Million Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Compass Capital Management Inc. reduced its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 0.9% in the second quarter, HoldingsChannel.com reports. The firm owned 102,839 shares of the medical research company’s stock after selling 941 shares during the period. Thermo Fisher Scientific comprises about 3.8% of Compass Capital Management Inc.’s investment portfolio, making the stock its 19th largest holding. Compass Capital Management Inc.’s holdings in Thermo Fisher Scientific were worth $56,870,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the stock. Summa Corp. purchased a new stake in shares of Thermo Fisher Scientific in the fourth quarter valued at about $418,000. Private Wealth Management Group LLC bought a new position in shares of Thermo Fisher Scientific during the 4th quarter worth approximately $110,000. Brookstone Capital Management grew its holdings in shares of Thermo Fisher Scientific by 252.4% in the first quarter. Brookstone Capital Management now owns 4,387 shares of the medical research company’s stock valued at $2,550,000 after acquiring an additional 3,142 shares in the last quarter. Y.D. More Investments Ltd lifted its holdings in Thermo Fisher Scientific by 33.9% during the fourth quarter. Y.D. More Investments Ltd now owns 391 shares of the medical research company’s stock worth $207,000 after acquiring an additional 99 shares during the period. Finally, Private Wealth Partners LLC grew its stake in Thermo Fisher Scientific by 1.0% in the 4th quarter. Private Wealth Partners LLC now owns 85,131 shares of the medical research company’s stock valued at $45,187,000 after purchasing an additional 815 shares during the period. Institutional investors own 89.23% of the company’s stock.

Insider Transactions at Thermo Fisher Scientific

In related news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction dated Wednesday, July 31st. The shares were sold at an average price of $617.21, for a total value of $6,172,100.00. Following the completion of the transaction, the chief executive officer now directly owns 123,816 shares of the company’s stock, valued at $76,420,473.36. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 300 shares of the stock in a transaction on Friday, July 26th. The stock was sold at an average price of $600.85, for a total value of $180,255.00. Following the completion of the transaction, the executive vice president now owns 17,887 shares in the company, valued at $10,747,403.95. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction on Wednesday, July 31st. The shares were sold at an average price of $617.21, for a total transaction of $6,172,100.00. Following the sale, the chief executive officer now owns 123,816 shares in the company, valued at approximately $76,420,473.36. The disclosure for this sale can be found here. In the last ninety days, insiders sold 33,084 shares of company stock valued at $19,767,092. Company insiders own 0.34% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on TMO. Robert W. Baird boosted their price target on shares of Thermo Fisher Scientific from $620.00 to $632.00 and gave the stock an “outperform” rating in a report on Thursday, July 25th. Jefferies Financial Group restated a “buy” rating and set a $650.00 price target (up previously from $600.00) on shares of Thermo Fisher Scientific in a research note on Monday, June 3rd. Stifel Nicolaus boosted their target price on Thermo Fisher Scientific from $600.00 to $615.00 and gave the company a “buy” rating in a research note on Thursday, July 25th. Royal Bank of Canada raised their price target on Thermo Fisher Scientific from $660.00 to $664.00 and gave the stock an “outperform” rating in a report on Thursday, July 25th. Finally, Evercore ISI lowered their target price on shares of Thermo Fisher Scientific from $615.00 to $600.00 and set an “outperform” rating on the stock in a research note on Tuesday, July 2nd. Five analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $618.94.

Thermo Fisher Scientific Trading Up 0.4 %

Shares of Thermo Fisher Scientific stock traded up $2.26 on Friday, hitting $606.12. The stock had a trading volume of 777,265 shares, compared to its average volume of 1,530,541. The stock’s 50-day simple moving average is $574.15 and its two-hundred day simple moving average is $573.81. Thermo Fisher Scientific Inc. has a one year low of $415.60 and a one year high of $622.30. The company has a quick ratio of 1.37, a current ratio of 1.72 and a debt-to-equity ratio of 0.64. The stock has a market cap of $231.37 billion, a price-to-earnings ratio of 38.88, a PEG ratio of 2.81 and a beta of 0.77.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Wednesday, July 24th. The medical research company reported $5.37 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.13 by $0.24. The firm had revenue of $10.54 billion for the quarter, compared to analysts’ expectations of $10.50 billion. Thermo Fisher Scientific had a net margin of 14.69% and a return on equity of 18.22%. The company’s revenue for the quarter was down 1.4% compared to the same quarter last year. During the same quarter in the previous year, the company earned $5.15 earnings per share. As a group, sell-side analysts predict that Thermo Fisher Scientific Inc. will post 21.72 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, October 15th. Shareholders of record on Friday, September 13th will be issued a $0.39 dividend. The ex-dividend date of this dividend is Friday, September 13th. This represents a $1.56 annualized dividend and a yield of 0.26%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 10.01%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.